Literature DB >> 18245516

Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma.

Akio Horiguchi1, Keiichi Ito, Makoto Sumitomo, Fumihiro Kimura, Tomohiko Asano, Masamichi Hayakawa.   

Abstract

BACKGROUND: Low levels of serum adiponectin are associated with increased risk and aggressiveness of obesity-related cancer. The purpose of the study reported here was to investigate the association between serum adiponectin levels and clinicopathological parameters of renal cell carcinoma.
METHODS: Preoperative serum total and high-molecular-weight (HMW) adiponectin levels were measured in 118 patients with renal cell carcinoma, and their association with clinicopathological parameters was analysed.
RESULTS: There were no statistically significant associations between total adiponectin and HMW adiponectin and pathological stage, regional lymph node involvement, histological grade, histological type (clear cell carcinoma versus other types) or presence of venous invasion. Total and HMW adiponectin levels in patients with metastasis, however, were significantly lower than in patients without metastasis (P = 0.044 for total adiponectin and P = 0.041 for HMW adiponectin). Low total and HMW adiponectin levels were significantly associated with metastasis in patients with a normal BMI (<25 kg/m(2)) (P = 0.034 for total adiponectin and P = 0.028 for HMW adiponectin) but not in overweight and obese patients (P = 0.652 for total adiponectin and P = 0.489 for HMW adiponectin). Multivariate logistic regression analysis showed that total adiponectin level was an independent predictor of metastasis of renal cell carcinoma in all patients (P = 0.024, 95% CI = 1.031-1.560) and in patients with a normal BMI (P = 0.040, 95% CI = 1.043-6.534).
CONCLUSIONS: Serum total and HMW adiponectin levels were decreased in patients with metastatic renal cell carcinoma. Adiponectin might be a molecular link between obesity and the progression of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245516     DOI: 10.1093/jjco/hym158

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  15 in total

1.  Adiponectin receptor expression in human malignant tissues.

Authors:  Sharon H Chou; Sofia Tseleni-Balafouta; Hyun-Seuk Moon; John P Chamberland; Xiaowen Liu; Nikolaos Kavantzas; Christos S Mantzoros
Journal:  Horm Cancer       Date:  2010-06       Impact factor: 3.869

Review 2.  The role of adiponectin in cancer: a review of current evidence.

Authors:  Maria Dalamaga; Kalliope N Diakopoulos; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2012-04-30       Impact factor: 19.871

3.  Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression.

Authors:  Nir Kleinmann; Wilhelmina C M Duivenvoorden; Sarah N Hopmans; Laura K Beatty; Shengjun Qiao; Daniel Gallino; Sarka Lhotak; Dean Daya; Athanasios Paschos; Richard C Austin; Jehonathan H Pinthus
Journal:  Clin Exp Metastasis       Date:  2013-10-05       Impact factor: 5.150

Review 4.  Adiponectin in insulin resistance: lessons from translational research.

Authors:  Florencia Ziemke; Christos S Mantzoros
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

5.  Association of adiponectin multimers with Barrett's oesophagus.

Authors:  J H Rubenstein; J Y Kao; R D Madanick; M Zhang; M Wang; M B Spacek; J L Donovan; S D Bright; N J Shaheen
Journal:  Gut       Date:  2009-06-30       Impact factor: 23.059

Review 6.  Effects of obesity on immune responses to renal tumors.

Authors:  Vincent Chehval; Lyse A Norian
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Renal cell cancer among African Americans: an epidemiologic review.

Authors:  Loren Lipworth; Robert E Tarone; Joseph K McLaughlin
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

8.  ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma.

Authors:  Guiming Zhang; Chengyuan Gu; Yao Zhu; Lei Luo; Dahai Dong; Fangning Wan; Hailiang Zhang; Guohai Shi; Lijiang Sun; Dingwei Ye
Journal:  Cancer Sci       Date:  2015-04-24       Impact factor: 6.716

Review 9.  Metabolic syndrome and renal cell carcinoma.

Authors:  Gui-Ming Zhang; Yao Zhu; Ding-Wei Ye
Journal:  World J Surg Oncol       Date:  2014-07-29       Impact factor: 2.754

10.  Endoplasmic reticulum protein ERp46 in renal cell carcinoma.

Authors:  Wilhelmina C M Duivenvoorden; Athanasios Paschos; Sarah N Hopmans; Richard C Austin; Jehonathan H Pinthus
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.